Overview of Dr. Geyer
Dr. Mark Geyer is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center (MSK) and Hackensack Meridian Health Riverview Medical Center. He received his undergraduate degree from Harvard College and his medical degree from Columbia University College of Physicians, and completed residency training at Massachusetts General Hospital before entering fellowship at MSK in 2014 and joining the MSK Leukemia Service in 2017. He specializes in hematologic malignancies.
Office
530 East 74th Street
New York, NY 10021Fax+1 929-321-8151
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2014
Columbia University Vagelos College of Physicians and SurgeonsClass of 2011
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2018 - 2025
NY State Medical License 2014 - 2025
NH State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
OK State Medical License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma Start of enrollment: 2021 Feb 02
Roles: Principal Investigator, Contact
- Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Start of enrollment: 2020 Mar 30
Roles: Principal Investigator, Contact
- A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia Start of enrollment: 2023 Aug 22
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 33 citationsNCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.Elizabeth A Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird
Journal of the National Comprehensive Cancer Network. 2022-05-01 - 272 citationsCD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.Jae H. Park, Mark B. Geyer, Renier J. Brentjens
Blood. 2016-06-30 - 49 citationsCord blood transplantation and stem cell regenerative potential.Yanling Liao, Mark B. Geyer, Albert J. Yang, Mitchell S. Cairo
Experimental Hematology. 2011-04-01
Abstracts/Posters
- Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...Mark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia PatientsMark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic LeukemiaMark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Looking Back to Go Forward: CAR-T Cell Therapy in R/R CLLJune 12th, 2019
Juno Therapeutics to Highlight CAR T Advances in B-cell Malignancies at ASH 2016November 3rd, 2016
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
